The routine commissioning of bevacizumab is accepted in Devon for rubeosis iridis and neovascular glaucoma.
| Filename: | Intravitreal bevacizumab for the management of rubeosis iridis and neovascular glaucoma |
| Filetype: | |
| Filesize: | 104.26 KB |
| Date uploaded: | 4th June 2018 |
| Date updated: | 8th December 2022 |
